Skip to main content

2017 | OriginalPaper | Buchkapitel

2. Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie

verfasst von : Prof. Dr. Gerhard Glatting, PD Dr. rer.nat. Carmen Wängler, Prof. Dr. rer. nat. Björn Wängler

Erschienen in: MR- und PET-Bildgebung der Prostata

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Im Gegensatz zu anderen bildgebenden Verfahren, welche zuvorderst die Anatomie des Patienten wiedergeben, stellt die PET eine Methode der Funktionsdiagnostik dar. Kapitel 2.1 stellt die physikalisch-technischen Grundlagen der PET vor. Dabei werden neben dem PET-Prinzip auch die eingesetzten Radionuklide, deren Eigenschaften und Herstellung, sowie Detektoren, Bildqualität sowie Akquisitions- und Auswertestrategien referiert. Die funktionelle Bildgebung des Prostatakarzinoms mittels PET ist in der Lage, die Erkrankung frühzeitig, sensitiv und spezifisch mittels verschiedener Mechanismen zu visualisieren und ist damit ein wertvolles Werkzeug für die primäre sowie Rezidivdiagnostik, die Einschätzung der Tumoraggressivität und des Therapieansprechens. Für die PET-Bildgebung des Prostatakarzinoms sind verschiedene Klassen von Radiotracern verfügbar, die eine unterschiedliche Eignung für die klinische Bildgebung der Erkrankung aufweisen. Kapitel 2.2 diskutiert die wichtigsten dieser Radiotracer.
Literatur
Zurück zum Zitat Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR (2011) Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. Journal of Nuclear Medicine 52:1970–1978 Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR (2011) Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. Journal of Nuclear Medicine 52:1970–1978
Zurück zum Zitat Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U (2015) The diagnostic value of PET-CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 42:197–209 Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U (2015) The diagnostic value of PET-CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 42:197–209
Zurück zum Zitat Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM (2013) PET imaging with a [Ga-68]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging 40:486–395 Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM (2013) PET imaging with a [Ga-68]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging 40:486–395
Zurück zum Zitat Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U (2014) Comparison of PET imaging with a Ga–68-labelled PSMA ligand and F–18-choline-based PET-CT for the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 41:11–20 Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U (2014) Comparison of PET imaging with a Ga–68-labelled PSMA ligand and F–18-choline-based PET-CT for the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 41:11–20
Zurück zum Zitat Akin O, Hricak H (2007) Imaging of prostate cancer. Radiologic Clinics of North America 45:207–222 Akin O, Hricak H (2007) Imaging of prostate cancer. Radiologic Clinics of North America 45:207–222
Zurück zum Zitat Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, Esaesser-Beile U, Buhler P (2010) High-resolution animal PET imaging of prostate cancer xenografts with three different Cu–64-labeled antibodies against native cell-adherent PSMA. Prostate 70:1413–1421 Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, Esaesser-Beile U, Buhler P (2010) High-resolution animal PET imaging of prostate cancer xenografts with three different Cu–64-labeled antibodies against native cell-adherent PSMA. Prostate 70:1413–1421
Zurück zum Zitat Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52:42s–55s Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52:42s–55s
Zurück zum Zitat Ananias HJK, De Jong IJ, Dierckx RA, van de Wiele C, Helfrich W, Elsinga PH (2008) Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des 14:3033–3047 Ananias HJK, De Jong IJ, Dierckx RA, van de Wiele C, Helfrich W, Elsinga PH (2008) Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des 14:3033–3047
Zurück zum Zitat Ananias HJK, van den Heuvel MC, Helfrich W, de Jong IJ (2009) Expression of the Gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69:1101–1108 Ananias HJK, van den Heuvel MC, Helfrich W, de Jong IJ (2009) Expression of the Gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69:1101–1108
Zurück zum Zitat Apolo AB, Pandit-Taskar N, Morris MJ (2008) Novel Tracers and Their Development for the Imaging of Metastatic prostate cancer. Journal of Nuclear Medicine 49:2031–2041 Apolo AB, Pandit-Taskar N, Morris MJ (2008) Novel Tracers and Their Development for the Imaging of Metastatic prostate cancer. Journal of Nuclear Medicine 49:2031–2041
Zurück zum Zitat Asano Y, Inoue Y, Ikeda Y, Kikuchi K, Hara T, Taguchi C, Tokushige T, Maruo H, Takeda T, Nakamura T, Fujita T, Kumagai Y, Hayakawa K (2011) Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[F–18]FACBC. Annals of Nuclear Medicine 25:414–318 Asano Y, Inoue Y, Ikeda Y, Kikuchi K, Hara T, Taguchi C, Tokushige T, Maruo H, Takeda T, Nakamura T, Fujita T, Kumagai Y, Hayakawa K (2011) Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[F–18]FACBC. Annals of Nuclear Medicine 25:414–318
Zurück zum Zitat Badin JR, Shied AF (2008) Imaging of cell proliferation: Status and prospects. Journal of Nuclear Medicine 49:64s–80s Badin JR, Shied AF (2008) Imaging of cell proliferation: Status and prospects. Journal of Nuclear Medicine 49:64s–80s
Zurück zum Zitat Bandari RP, Jiang ZR, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ (2014) Synthesis and biological evaluation of copper-64 radiolabeled [DUPA–6-Ahx-(NODAGA)–5-Ava-BBN(7–14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nuclear Medicine and Biology 41:355–363 Bandari RP, Jiang ZR, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ (2014) Synthesis and biological evaluation of copper-64 radiolabeled [DUPA–6-Ahx-(NODAGA)–5-Ava-BBN(7–14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nuclear Medicine and Biology 41:355–363
Zurück zum Zitat Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of (177)lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 23:4591–3601 Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of (177)lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 23:4591–3601
Zurück zum Zitat Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. Journal of Urology 170:1717–1721 Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. Journal of Urology 170:1717–1721
Zurück zum Zitat Banerjee SR, Foss CA, Pullambhatla M, Wang YC, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG (2015) Preclinical Evaluation of Y–86-labeled inhibitors of prostate specific membrane antigen for dosimetry estimates. Journal of Nuclear Medicine 56:628–634 Banerjee SR, Foss CA, Pullambhatla M, Wang YC, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG (2015) Preclinical Evaluation of Y–86-labeled inhibitors of prostate specific membrane antigen for dosimetry estimates. Journal of Nuclear Medicine 56:628–634
Zurück zum Zitat Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG (2010) Ga-68-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. Journal of Medicinal Chemistry 53:5333–5341 Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG (2010) Ga-68-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. Journal of Medicinal Chemistry 53:5333–5341
Zurück zum Zitat Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Erson CJ, Mease RC, Pomper MG (2014) Cu-64-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. Journal of Medicinal Chemistry 57:2657–2669 Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Erson CJ, Mease RC, Pomper MG (2014) Cu-64-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. Journal of Medicinal Chemistry 57:2657–2669
Zurück zum Zitat Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC, Pomper MG, Lubkowski J (2008) Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. Journal of Medicinal Chemistry 51:7737–7743 Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC, Pomper MG, Lubkowski J (2008) Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. Journal of Medicinal Chemistry 51:7737–7743
Zurück zum Zitat Barinka C, Rovenska M, Mlcochova P, Hlouchova K, Plechanovova A, Majer P, Tsukamoto T, Slusher BS, Konvalinka J, Lubkowski J (2007) Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. Journal of Medicinal Chemistry 50:3267–3273 Barinka C, Rovenska M, Mlcochova P, Hlouchova K, Plechanovova A, Majer P, Tsukamoto T, Slusher BS, Konvalinka J, Lubkowski J (2007) Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. Journal of Medicinal Chemistry 50:3267–3273
Zurück zum Zitat Beattie BJ, Smith-Jones PM, Jhanwar YS, Schoder H, Schmidtlein CR, Morris MJ, Zanzonico P, Squire O, Meirelles GSP, Finn R, Namavari M, Cai SD, Scher HI, Larson SM, Humm JL (2010) Pharmacokinetic Assessment of the Uptake of 16 beta-F-18-Fluoro-5 alpha-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET. Journal of Nuclear Medicine 51:183–192 Beattie BJ, Smith-Jones PM, Jhanwar YS, Schoder H, Schmidtlein CR, Morris MJ, Zanzonico P, Squire O, Meirelles GSP, Finn R, Namavari M, Cai SD, Scher HI, Larson SM, Humm JL (2010) Pharmacokinetic Assessment of the Uptake of 16 beta-F-18-Fluoro-5 alpha-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET. Journal of Nuclear Medicine 51:183–192
Zurück zum Zitat Beheshti M, Hai S, Zakav R, Steinmai M, Waldenberge P, Kuni T, Nade M, Langstege W, Loid, W (2013a) Impact of F-18-Choline PET-CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. Journal of Nuclear Medicine 54:833–884 Beheshti M, Hai S, Zakav R, Steinmai M, Waldenberge P, Kuni T, Nade M, Langstege W, Loid, W (2013a) Impact of F-18-Choline PET-CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. Journal of Nuclear Medicine 54:833–884
Zurück zum Zitat Beheshti M, Imamovic, L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W (2010) F-18 Choline PET-CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254:925–933 Beheshti M, Imamovic, L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W (2010) F-18 Choline PET-CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254:925–933
Zurück zum Zitat Beheshti M, Langsteger W, Sommerhuber A, Steinmair M, Wolf I, Valencia R, Lesche R, Nader M, Piert M, Loidl W (2012) BAY 1075553 PET-CT in staging and re-staging of prostate cancer patients – phase I study and comparison to 18F-FCH. Journal of Nuclear Medicine 53:272 Beheshti M, Langsteger W, Sommerhuber A, Steinmair M, Wolf I, Valencia R, Lesche R, Nader M, Piert M, Loidl W (2012) BAY 1075553 PET-CT in staging and re-staging of prostate cancer patients – phase I study and comparison to 18F-FCH. Journal of Nuclear Medicine 53:272
Zurück zum Zitat Beheshti M, Treglia G, Zakavi R, Langsteger W, Ghodsi RMA, Dabbagh KVR, Sadeghi R (2013b) Application of 11C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. Bju International 112:1062–1072 Beheshti M, Treglia G, Zakavi R, Langsteger W, Ghodsi RMA, Dabbagh KVR, Sadeghi R (2013b) Application of 11C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. Bju International 112:1062–1072
Zurück zum Zitat Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M (2015) Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. Journal of Nuclear Medicine 56:914–920 Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M (2015) Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. Journal of Nuclear Medicine 56:914–920
Zurück zum Zitat Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S (2003) Dual-modality PET-CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30 (4):588–596 Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S (2003) Dual-modality PET-CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30 (4):588–596
Zurück zum Zitat Beyer T, Rosenbaum S, Veit P, Stattaus J, Müller SP, DiFilippo FP, Schöder H, Mawlawi O, Roberts F, Bockisch A, Kühl H (2005) Respiration artifacts in whole-body 18F-FDG PET-CT studies with combined PET-CT tomographs employing spiral CT technology with 1 to 16 detector rows. Eur J Nucl Med Mol Imaging 32 (12):1429–1439. doi:10.1007/s00259–005–1879–8 Beyer T, Rosenbaum S, Veit P, Stattaus J, Müller SP, DiFilippo FP, Schöder H, Mawlawi O, Roberts F, Bockisch A, Kühl H (2005) Respiration artifacts in whole-body 18F-FDG PET-CT studies with combined PET-CT tomographs employing spiral CT technology with 1 to 16 detector rows. Eur J Nucl Med Mol Imaging 32 (12):1429–1439. doi:10.1007/s00259–005–1879–8
Zurück zum Zitat Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R (2000) A combined PET-CT scanner for clinical oncology. J Nucl Med 41 (8):1369–1379 Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R (2000) A combined PET-CT scanner for clinical oncology. J Nucl Med 41 (8):1369–1379
Zurück zum Zitat Birtle AJ, Freeman A, Masters JRW, Payne HA, Harland SJ, Registr BSOC (2005) Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of < 10 ng/ml. Bju International 96:303–307 Birtle AJ, Freeman A, Masters JRW, Payne HA, Harland SJ, Registr BSOC (2005) Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of < 10 ng/ml. Bju International 96:303–307
Zurück zum Zitat Bollinen VR, Krame GM, Jansm EP, Li Y, Oye WJ (2016) A systematic review on [F]FLT-PET uptake as a measure of treatment response in cancer patients. European Journal of Cancer 55:81–97 Bollinen VR, Krame GM, Jansm EP, Li Y, Oye WJ (2016) A systematic review on [F]FLT-PET uptake as a measure of treatment response in cancer patients. European Journal of Cancer 55:81–97
Zurück zum Zitat Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma - A study of 184 cases. Cancer 82:2256–2261 Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma - A study of 184 cases. Cancer 82:2256–2261
Zurück zum Zitat Brogsitter C, Zophel K, Kotzerke J (2013) F-18-Choline, C-11-choline and C-11-acetate PET-CT: comparative analysis for imaging prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 40:S18–S27 Brogsitter C, Zophel K, Kotzerke J (2013) F-18-Choline, C-11-choline and C-11-acetate PET-CT: comparative analysis for imaging prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 40:S18–S27
Zurück zum Zitat Brooks RA, Di Chiro G (1976) Principles of computer assisted tomography (CAT) in radiographic and radioisotopic imaging. Phys Med Biol 21 (5):689–732 Brooks RA, Di Chiro G (1976) Principles of computer assisted tomography (CAT) in radiographic and radioisotopic imaging. Phys Med Biol 21 (5):689–732
Zurück zum Zitat Brownell GL (1999) A History of Positron Imaging. Physics Research Laboratory, Massachusetts General Hospital, Division of Radiological Sciences, Massachusetts Institute of Technology. S1–11 Brownell GL (1999) A History of Positron Imaging. Physics Research Laboratory, Massachusetts General Hospital, Division of Radiological Sciences, Massachusetts Institute of Technology. S1–11
Zurück zum Zitat Burger C, Goerres G, Schoenes S, Buck A, Lonn AH, Von-Schulthess GK (2002) PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 29 (7):922–927 Burger C, Goerres G, Schoenes S, Buck A, Lonn AH, Von-Schulthess GK (2002) PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 29 (7):922–927
Zurück zum Zitat Carlucci G, Kuipers A, Ananias HJK, Faria DD, Dierckx RAJO, Helfrich W, Rink R, Moll GN, de Jong IJ, Elsinga PH (2015) GRPR-selective PET imaging of prostate cancer using [F-18]-bombesin analogs. Peptides 67:45–54 Carlucci G, Kuipers A, Ananias HJK, Faria DD, Dierckx RAJO, Helfrich W, Rink R, Moll GN, de Jong IJ, Elsinga PH (2015) GRPR-selective PET imaging of prostate cancer using [F-18]-bombesin analogs. Peptides 67:45–54
Zurück zum Zitat Casey ME, Nutt R (1986) Multicrystal two dimensional BGO detector systems for positron emission tomography. IEEE Trans Nucl Sci 33:469–363 Casey ME, Nutt R (1986) Multicrystal two dimensional BGO detector systems for positron emission tomography. IEEE Trans Nucl Sci 33:469–363
Zurück zum Zitat Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini I (2015) Ga-68-PSMA PET-CT for restaging recurrent prostate cancer: which factors are associated with PET-CT detection rate? European Journal of Nuclear Medicine and Molecular Imaging 42:1284–1294 Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini I (2015) Ga-68-PSMA PET-CT for restaging recurrent prostate cancer: which factors are associated with PET-CT detection rate? European Journal of Nuclear Medicine and Molecular Imaging 42:1284–1294
Zurück zum Zitat Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49:318–326 Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49:318–326
Zurück zum Zitat Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB (1999a) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clinical Cancer Research 5:2674–2681 Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB (1999a) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clinical Cancer Research 5:2674–2681
Zurück zum Zitat Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB (1999b) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Research 59:3192–3198 Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB (1999b) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Research 59:3192–3198
Zurück zum Zitat Chang SS, Reuter VE, Heston WDW, Gaudin PB (2001) Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 57:801–805 Chang SS, Reuter VE, Heston WDW, Gaudin PB (2001) Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 57:801–805
Zurück zum Zitat Chatalic KLS, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M (2014) Preclinical comparison of (AlF)-F-18- and Ga-68-labeled Gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. Journal of Nuclear Medicine 55:2050–2056 Chatalic KLS, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M (2014) Preclinical comparison of (AlF)-F-18- and Ga-68-labeled Gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. Journal of Nuclear Medicine 55:2050–2056
Zurück zum Zitat Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambahatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry 51:7933–7943 Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambahatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry 51:7933–7943
Zurück zum Zitat Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, Slusher BS, Mease RC, Pomper MG (2012) Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjugate Chemistry 23:2377–2385 Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, Slusher BS, Mease RC, Pomper MG (2012) Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjugate Chemistry 23:2377–2385
Zurück zum Zitat Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG (2011) 2-(3-{1-Carboxy–5-[(6-[F-18]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic acid, [F-18]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clinical Cancer Research 17:7645–7653 Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG (2011) 2-(3-{1-Carboxy–5-[(6-[F-18]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic acid, [F-18]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clinical Cancer Research 17:7645–7653
Zurück zum Zitat Cherry SR, Sorenson JA, Phelps ME (2012) Physics in Nuclear Medicine. 4th edition Aufl. Elsevier Saunders, Philadelphia PA19103–2899 Cherry SR, Sorenson JA, Phelps ME (2012) Physics in Nuclear Medicine. 4th edition Aufl. Elsevier Saunders, Philadelphia PA19103–2899
Zurück zum Zitat Chikkaveeraiah BV, Bhirde A, Malhotra R, Patel V, Gutkind JS, Rusling JF (2009) Single-Wall Carbon Nanotube Forest Arrays for Immunoelectrochemical Measurement of Four Protein Biomarkers for prostate cancer. Analytical Chemistry 81:9129–9134 Chikkaveeraiah BV, Bhirde A, Malhotra R, Patel V, Gutkind JS, Rusling JF (2009) Single-Wall Carbon Nanotube Forest Arrays for Immunoelectrochemical Measurement of Four Protein Biomarkers for prostate cancer. Analytical Chemistry 81:9129–9134
Zurück zum Zitat Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG (2012) Biodistribution, tumor detection, and radiation dosimetry of F-18-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. Journal of Nuclear Medicine 53:1883–1891 Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG (2012) Biodistribution, tumor detection, and radiation dosimetry of F-18-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. Journal of Nuclear Medicine 53:1883–1891
Zurück zum Zitat Cimitan M, Bortolu R, Morassu S, Canzonier V, Garbegli A, Baresi T, Borsatt, E, Drig A, Trov MG (2006) [F-18]fluorocholine PET-CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. European Journal of Nuclear Medicine and Molecular Imaging 33:1387–1390 Cimitan M, Bortolu R, Morassu S, Canzonier V, Garbegli A, Baresi T, Borsatt, E, Drig A, Trov MG (2006) [F-18]fluorocholine PET-CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. European Journal of Nuclear Medicine and Molecular Imaging 33:1387–1390
Zurück zum Zitat Conti M, Eriksson L (2016) Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys 3:8 Conti M, Eriksson L (2016) Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys 3:8
Zurück zum Zitat Conti M, Eriksson L (2016) Physics of pure and non-pure positron emitters for PET: a review and a discussion.« EJNMMI Physics 3(1): 1–17 Conti M, Eriksson L (2016) Physics of pure and non-pure positron emitters for PET: a review and a discussion.« EJNMMI Physics 3(1): 1–17
Zurück zum Zitat Conway RE, Petrovic N, Li Z, Heston W, Wu DQ, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Molecular and Cellular Biology 26:5310–5324 Conway RE, Petrovic N, Li Z, Heston W, Wu DQ, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Molecular and Cellular Biology 26:5310–5324
Zurück zum Zitat Cornelio DB, Roesler R, Schwartsmann G (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Annals of Oncology 18:1457–1466 Cornelio DB, Roesler R, Schwartsmann G (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Annals of Oncology 18:1457–1466
Zurück zum Zitat D’Asseler Y, Vandenberghe S, Winter FD, Van de Walle R, Koole M, Bouwens L, Lemahieu I, Dierckx RA (2001) PET imaging using gamma cameras. Computerized Medical Imaging and Graphics 25 (2):87–96. doi:10.1016/s0895–6111(00)00058–6 D’Asseler Y, Vandenberghe S, Winter FD, Van de Walle R, Koole M, Bouwens L, Lemahieu I, Dierckx RA (2001) PET imaging using gamma cameras. Computerized Medical Imaging and Graphics 25 (2):87–96. doi:10.1016/s0895–6111(00)00058–6
Zurück zum Zitat Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO, Giangrande PH (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839–849 Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO, Giangrande PH (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839–849
Zurück zum Zitat Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ (2005) Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proceedings of the National Academy of Sciences of the United States of America 102:5981–5986 Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ (2005) Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proceedings of the National Academy of Sciences of the United States of America 102:5981–5986
Zurück zum Zitat De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by C-11-choline PET. Journal of Nuclear Medicine 44:331–335 De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by C-11-choline PET. Journal of Nuclear Medicine 44:331–335
Zurück zum Zitat Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, Welch MJ (2005) Positron tomographic assessment of androgen receptors in prostatic carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 32:344–350 Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, Welch MJ (2005) Positron tomographic assessment of androgen receptors in prostatic carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 32:344–350
Zurück zum Zitat Demirkol MO, Acar O, Ucar B, Ramazanoglu SR, Saglican Y, Esen T (2015) prostate-specific membrane antigen-based imaging in prostate cancer: Impact on Clinical Decision Making Process. Prostate 75:748–757 Demirkol MO, Acar O, Ucar B, Ramazanoglu SR, Saglican Y, Esen T (2015) prostate-specific membrane antigen-based imaging in prostate cancer: Impact on Clinical Decision Making Process. Prostate 75:748–757
Zurück zum Zitat Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B (2015) Comparison of [F-18]DCFPyL and [Ga-68]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Molecular Imaging and Biology 17:575–584 Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B (2015) Comparison of [F-18]DCFPyL and [Ga-68]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Molecular Imaging and Biology 17:575–584
Zurück zum Zitat Durkan K, Jiang ZR, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu LQ, Miao YB, Reynolds TS, Smith CJ (2014) A heterodimeric [RGD-Glu-[Cu–64-NO2A]–6-Ahx-RM2] alpha(v)beta(3)/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nuclear Medicine and Biology 41:133–139 Durkan K, Jiang ZR, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu LQ, Miao YB, Reynolds TS, Smith CJ (2014) A heterodimeric [RGD-Glu-[Cu–64-NO2A]–6-Ahx-RM2] alpha(v)beta(3)/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nuclear Medicine and Biology 41:133–139
Zurück zum Zitat Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kubler H, Haberhorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M (2015) Evaluation of hybrid Ga-68-PSMA ligand PET-CT in 248 patients with biochemical recurrence after radical prostatectomy. Journal of Nuclear Medicine 56:668–674 Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kubler H, Haberhorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M (2015) Evaluation of hybrid Ga-68-PSMA ligand PET-CT in 248 patients with biochemical recurrence after radical prostatectomy. Journal of Nuclear Medicine 56:668–674
Zurück zum Zitat Eder M, Schafer M, Bauder-Wust U, Haberkorn U, Eisenhut M, Kopka, K (2014) Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74:659–668 Eder M, Schafer M, Bauder-Wust U, Haberkorn U, Eisenhut M, Kopka, K (2014) Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74:659–668
Zurück zum Zitat Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, Haberkorn U, Eisenhut M (2012) Ga–68-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjugate Chemistry 23:688–697 Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, Haberkorn U, Eisenhut M (2012) Ga–68-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjugate Chemistry 23:688–697
Zurück zum Zitat Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G (1996) Metabolic imaging of untreated prostate cancer by positron emission tomography with (18)fluorine-labeled deoxyglucose. Journal of Urology 155:994–998 Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G (1996) Metabolic imaging of untreated prostate cancer by positron emission tomography with (18)fluorine-labeled deoxyglucose. Journal of Urology 155:994–998
Zurück zum Zitat Effert PJ, Beniers AJ, Tamimi Y, Handt S, Jakse G (2004) Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Research 24:3057–3063 Effert PJ, Beniers AJ, Tamimi Y, Handt S, Jakse G (2004) Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Research 24:3057–3063
Zurück zum Zitat Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66:1359–1370 Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66:1359–1370
Zurück zum Zitat Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L (2015) F-18-fluoromethylcholine or F-18-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. Nuclear Medicine and Biology 42:340–348 Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L (2015) F-18-fluoromethylcholine or F-18-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. Nuclear Medicine and Biology 42:340–348
Zurück zum Zitat Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL (2011) Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America 108:9578–9582 Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL (2011) Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America 108:9578–9582
Zurück zum Zitat Foss CA, Mease RC, Fan H, Wang YC, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clinical Cancer Research 11:4022–3028 Foss CA, Mease RC, Fan H, Wang YC, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clinical Cancer Research 11:4022–3028
Zurück zum Zitat Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR (2003) Positron emission tomography with C-11-acetate and F-18-FDG in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 30, 607–611 Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR (2003) Positron emission tomography with C-11-acetate and F-18-FDG in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 30, 607–611
Zurück zum Zitat Geworski L, Knoop BO, de-Cabrejas ML, Knapp WH, Munz DL (2000) Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med 27(2):161–169 Geworski L, Knoop BO, de-Cabrejas ML, Knapp WH, Munz DL (2000) Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med 27(2):161–169
Zurück zum Zitat Ghosh A, Heston WDW (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. Journal of Cellular Biochemistry 91:528–539 Ghosh A, Heston WDW (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. Journal of Cellular Biochemistry 91:528–539
Zurück zum Zitat Glatting G, Kletting P, Reske SN, Hohl K, Ring C (2007) Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test. Med Phys 34 (11):4285–3292 Glatting G, Kletting P, Reske SN, Hohl K, Ring C (2007) Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test. Med Phys 34 (11):4285–3292
Zurück zum Zitat Glatting G, Mottaghy FM, Baune A, Sommer TF, Landwehrmeyer GB, Reske SN (2004) Improving binding potenzial analysis in [11C]raclopride PET studies using cluster analysis. Med Phys 31 (4):902–906 Glatting G, Mottaghy FM, Baune A, Sommer TF, Landwehrmeyer GB, Reske SN (2004) Improving binding potenzial analysis in [11C]raclopride PET studies using cluster analysis. Med Phys 31 (4):902–906
Zurück zum Zitat Glatting G, Werner C, Reske SN, Bellemann ME (2003) ROC analysis for assessment of lesion detection performance in 3D PET: Influence of reconstruction algorithms. Med Phys 30 (9):2315–2319 Glatting G, Werner C, Reske SN, Bellemann ME (2003) ROC analysis for assessment of lesion detection performance in 3D PET: Influence of reconstruction algorithms. Med Phys 30 (9):2315–2319
Zurück zum Zitat Goerres GW, Kamel E, Heidelberg TN, Schwitter MR, Burger C, von-Schulthess GK (2002) PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging 29 (3):351–360 Goerres GW, Kamel E, Heidelberg TN, Schwitter MR, Burger C, von-Schulthess GK (2002) PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging 29 (3):351–360
Zurück zum Zitat Gourni E, Del Pozzo L, Kheirallah E, Smerling C, Waser B, Reubi JC, Paterson BM, Donnelly PS, Meyer PT, Maecke HR (2015) Copper-64 labeled macrobicyclic sarcophagine coupled to a GRP receptor antagonist shows great promise for PET imaging of prostate cancer. Molecular Pharmaceutics 12:2781–2790 Gourni E, Del Pozzo L, Kheirallah E, Smerling C, Waser B, Reubi JC, Paterson BM, Donnelly PS, Meyer PT, Maecke HR (2015) Copper-64 labeled macrobicyclic sarcophagine coupled to a GRP receptor antagonist shows great promise for PET imaging of prostate cancer. Molecular Pharmaceutics 12:2781–2790
Zurück zum Zitat Gunn RN, Gunn SR, Cunningham VJ (2001) Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21 (6):635–652 Gunn RN, Gunn SR, Cunningham VJ (2001) Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21 (6):635–652
Zurück zum Zitat Gunn RN, Gunn SR, Turkheimer FE, Aston JA, Cunningham VJ (2002) Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 22 (12):1425–1439 Gunn RN, Gunn SR, Turkheimer FE, Aston JA, Cunningham VJ (2002) Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 22 (12):1425–1439
Zurück zum Zitat Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, Ofner D, Zelger B, Ensinger C, Yang XMJ, Geley S, Margreiter R, Bander NH (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human Pathology 40:1754–1761 Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, Ofner D, Zelger B, Ensinger C, Yang XMJ, Geley S, Margreiter R, Bander NH (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human Pathology 40:1754–1761
Zurück zum Zitat Haseman MK, Rosenthal SA, Polascik TJ (2000) Capromab pendetide imaging of prostate cancer. Cancer Biotherapy and Radiopharmaceuticals 15:131–140 Haseman MK, Rosenthal SA, Polascik TJ (2000) Capromab pendetide imaging of prostate cancer. Cancer Biotherapy and Radiopharmaceuticals 15:131–140
Zurück zum Zitat Herman GT, Lent A (1976) Iterative reconstruction algorithms. Comput Biol Med 6 (4):273–294 Herman GT, Lent A (1976) Iterative reconstruction algorithms. Comput Biol Med 6 (4):273–294
Zurück zum Zitat Herzog H (2012) PET/MRI: Challenges, solutions and perspectives. Z Med Phys 22 (4):281–298. doi:http://dx.doi.org/10.1016/j.zemedi.2012.07.003 Herzog H (2012) PET/MRI: Challenges, solutions and perspectives. Z Med Phys 22 (4):281–298. doi:http://​dx.​doi.​org/​10.​1016/​j.​zemedi.​2012.​07.​003
Zurück zum Zitat Herzog H, Lerche C (2016) Advances in Clinical PET/MRI Instrumentation. PET Clinics 11 (2):95–103. doi:10.1016/j.cpet.2015.09.001 Herzog H, Lerche C (2016) Advances in Clinical PET/MRI Instrumentation. PET Clinics 11 (2):95–103. doi:10.1016/j.cpet.2015.09.001
Zurück zum Zitat Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. European Urology 36:31–35 Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. European Urology 36:31–35
Zurück zum Zitat Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS (2010) Zr–89-DFO-J591 for ImmunoPET of prostate-specific membrane antigen Expression In Vivo. Journal of Nuclear Medicine 51:1293–1300 Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS (2010) Zr–89-DFO-J591 for ImmunoPET of prostate-specific membrane antigen Expression In Vivo. Journal of Nuclear Medicine 51:1293–1300
Zurück zum Zitat Huang S-C, Phelps ME (1986a) Parameter estimation in positron emission tomography. In: Phelps ME, Mazziotta J, Schelbert H (Hrsg) Positron emission tomography and autoradiography: Principles and applications for the brain and heart. Raven Press, New York, S 347–390 Huang S-C, Phelps ME (1986a) Parameter estimation in positron emission tomography. In: Phelps ME, Mazziotta J, Schelbert H (Hrsg) Positron emission tomography and autoradiography: Principles and applications for the brain and heart. Raven Press, New York, S 347–390
Zurück zum Zitat Huang S-C, Phelps ME (1986b) Principles of tracer kinetic modeling in positron emission tomography. In: Phelps ME, Mazziotta J, Schelbert H (Hrsg) Positron emission tomography and autoradiography: Principles and applications for the brain and heart. Raven Press, New York, S 287–346 Huang S-C, Phelps ME (1986b) Principles of tracer kinetic modeling in positron emission tomography. In: Phelps ME, Mazziotta J, Schelbert H (Hrsg) Positron emission tomography and autoradiography: Principles and applications for the brain and heart. Raven Press, New York, S 287–346
Zurück zum Zitat Igerc I, Kohlfurst S, Gallowitsch HJ, Matschnig S, Kresnik E, Gomez-Segovia I, Lind P (2008) The value of F-18-choline PET-CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 35:976–983 Igerc I, Kohlfurst S, Gallowitsch HJ, Matschnig S, Kresnik E, Gomez-Segovia I, Lind P (2008) The value of F-18-choline PET-CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 35:976–983
Zurück zum Zitat International Commission on Radiation Units and Measurements (1996) ICRU Report 54. Medical Imaging – The Assessment of Image Quality. ICRU Reports., Bethesda, Maryland 20814, USA International Commission on Radiation Units and Measurements (1996) ICRU Report 54. Medical Imaging – The Assessment of Image Quality. ICRU Reports., Bethesda, Maryland 20814, USA
Zurück zum Zitat Iriarte A, Marabini R, Matej S, Sorzano COS, Lewitt RM (2016) System models for PET statistical iterative reconstruction: A review. Computerized Medical Imaging and Graphics 48:30–38. doi:http://dx.doi.org/10.1016/j.compmedimag.2015.12.003 Iriarte A, Marabini R, Matej S, Sorzano COS, Lewitt RM (2016) System models for PET statistical iterative reconstruction: A review. Computerized Medical Imaging and Graphics 48:30–38. doi:http://​dx.​doi.​org/​10.​1016/​j.​compmedimag.​2015.​12.​003
Zurück zum Zitat Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW (1994) Expression of the prostate-specific membrane antigen. Cancer Research 54:1807–1811 Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW (1994) Expression of the prostate-specific membrane antigen. Cancer Research 54:1807–1811
Zurück zum Zitat Jadvar H (2011) prostate cancer: PET with F-18-FDG, F-18- or C-11-Acetate, and F–18- or C-11-Choline. Journal of Nuclear Medicine 52, 81–89 Jadvar H (2011) prostate cancer: PET with F-18-FDG, F-18- or C-11-Acetate, and F–18- or C-11-Choline. Journal of Nuclear Medicine 52, 81–89
Zurück zum Zitat Jadvar H, Chen K, Ukimura O (2015) Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET-CT. Clinical Nuclear Medicine 40, E426-E428 Jadvar H, Chen K, Ukimura O (2015) Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET-CT. Clinical Nuclear Medicine 40, E426-E428
Zurück zum Zitat Jadvar H, Ya LP, Par RLZB, Che K, Hughe L, Kouh A, Cont P (2012) [F-18]-2’-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F–18-FMAU) in prostate cancer: Initial Preclinical Observations. Molecular Imaging 11:426–332 Jadvar H, Ya LP, Par RLZB, Che K, Hughe L, Kouh A, Cont P (2012) [F-18]-2’-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F–18-FMAU) in prostate cancer: Initial Preclinical Observations. Molecular Imaging 11:426–332
Zurück zum Zitat Jana S, Blaufox MD (2006) Nuclear medicine studies of the prostate, testes, and bladder. Seminars in Nuclear Medicine 36, 51–72 Jana S, Blaufox MD (2006) Nuclear medicine studies of the prostate, testes, and bladder. Seminars in Nuclear Medicine 36, 51–72
Zurück zum Zitat Joshua WC, Craig SL (2016) Advances in coincidence time resolution for PET. Phys Med Biol 61 (6):2255–2264 Joshua WC, Craig SL (2016) Advances in coincidence time resolution for PET. Phys Med Biol 61 (6):2255–2264
Zurück zum Zitat Kahkonen E, Jambor I, Kemppainen J, Lehtio K, Gronroos TJ, Kuisma A, Luoto P, Sipila HJ, Tolvanen T, Alanen K, Silen J, Kallajoki M, Roivainen A, Schafer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H (2013) In vivo imaging of prostate cancer using [Ga-68]-labeled bombesin analog BAY86–7548. Clinical Cancer Research 19:5434–5443 Kahkonen E, Jambor I, Kemppainen J, Lehtio K, Gronroos TJ, Kuisma A, Luoto P, Sipila HJ, Tolvanen T, Alanen K, Silen J, Kallajoki M, Roivainen A, Schafer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H (2013) In vivo imaging of prostate cancer using [Ga-68]-labeled bombesin analog BAY86–7548. Clinical Cancer Research 19:5434–5443
Zurück zum Zitat Kairemo K, Rasulova N, Partanen K, Joensuu T (2014) Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) PET-CT imaging in prostate cancer patients. Biomed Research International:305182 Kairemo K, Rasulova N, Partanen K, Joensuu T (2014) Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) PET-CT imaging in prostate cancer patients. Biomed Research International:305182
Zurück zum Zitat Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, Katoh C, Nakada K, Tamaki N (2002) Accumulation of [C-11]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 29:1492–1495 Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, Katoh C, Nakada K, Tamaki N (2002) Accumulation of [C-11]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 29:1492–1495
Zurück zum Zitat Kelloff GJ, Choyke P, Coffey DS (2009) Challenges in Clinical prostate cancer: Role of Imaging. American Journal of Roentgenology 192:1455–1470 Kelloff GJ, Choyke P, Coffey DS (2009) Challenges in Clinical prostate cancer: Role of Imaging. American Journal of Roentgenology 192:1455–1470
Zurück zum Zitat Keyes JW (1995) SUV: Standard uptake or silly useless value? J Nucl Med 36 (10):1836–1839 Keyes JW (1995) SUV: Standard uptake or silly useless value? J Nucl Med 36 (10):1836–1839
Zurück zum Zitat Kinahan PE, Townsend DW, Beyer T, Sashin D (1998) Attenuation correction for a combined 3D PET-CT scanner. Med Phys 25 (10):2046–2053 Kinahan PE, Townsend DW, Beyer T, Sashin D (1998) Attenuation correction for a combined 3D PET-CT scanner. Med Phys 25 (10):2046–2053
Zurück zum Zitat Kitajima K, Murphy RC, Nathan MA (2013) Choline PET-CT for imaging prostate cancer: an update. Annals of Nuclear Medicine 27:581–591 Kitajima K, Murphy RC, Nathan MA (2013) Choline PET-CT for imaging prostate cancer: an update. Annals of Nuclear Medicine 27:581–591
Zurück zum Zitat Kletting P, Schimmel S, Kestler HA, Hänscheid H, Luster M, Fernández M, Bröer JH, Nosske D, Lassmann M, Glatting G (2013) Molecular radiotherapy: The NUKFIT software for calculating the time-integrated activity coefficient. Med Phys 40 (10):102504 Kletting P, Schimmel S, Kestler HA, Hänscheid H, Luster M, Fernández M, Bröer JH, Nosske D, Lassmann M, Glatting G (2013) Molecular radiotherapy: The NUKFIT software for calculating the time-integrated activity coefficient. Med Phys 40 (10):102504
Zurück zum Zitat Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, Mottaghy FM, Behrendt FF (2015) 68Ga-68-PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. European Journal of Nuclear Medicine and Molecular Imaging 42:210–214 Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, Mottaghy FM, Behrendt FF (2015) 68Ga-68-PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. European Journal of Nuclear Medicine and Molecular Imaging 42:210–214
Zurück zum Zitat Kusumi T, Koie T, Tanaka M, Matsumoto K, Sato F, Kusumi A, Ohyama C, Kijima H (2008) Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathology International 58:687–694 Kusumi T, Koie T, Tanaka M, Matsumoto K, Sato F, Kusumi A, Ohyama C, Kijima H (2008) Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathology International 58:687–694
Zurück zum Zitat Langsteger W, Kunit T, Haim S, Nader M, Valencia R, Lesche R, Sega W, Piert M, Loidl W, Beheshti M (2012) BAY 1075553 PET-CT in the assessment of prostate cancer: safety, tolerability and biodistribution – phase I first in human study results. Journal of Nuclear Medicine 53:1125 Langsteger W, Kunit T, Haim S, Nader M, Valencia R, Lesche R, Sega W, Piert M, Loidl W, Beheshti M (2012) BAY 1075553 PET-CT in the assessment of prostate cancer: safety, tolerability and biodistribution – phase I first in human study results. Journal of Nuclear Medicine 53:1125
Zurück zum Zitat Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu TC, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF (2009) Assessment of an F-18-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Journal of Nuclear Medicine 50:2042–2048 Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu TC, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF (2009) Assessment of an F-18-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Journal of Nuclear Medicine 50:2042–2048
Zurück zum Zitat Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS (2000) Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 45:350–354 Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS (2000) Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 45:350–354
Zurück zum Zitat Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H (2004) Tumor localization of 16 beta-F-18-fluoro–5 alpha-dihydrotestosterone vs. F–18-FDG in patients with progressive, metastatic prostate cancer. Journal of Nuclear Medicine 45:366–373 Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H (2004) Tumor localization of 16 beta-F-18-fluoro–5 alpha-dihydrotestosterone vs. F–18-FDG in patients with progressive, metastatic prostate cancer. Journal of Nuclear Medicine 45:366–373
Zurück zum Zitat Lesche R, Kettschau G, Gromov AV, Bohnke N, Borkowski S, Monning U, Hegele-Hartung C, Dohr O, Dinkelborg LM, Graham K (2014) Preclinical evaluation of BAY 1075553, a novel F-18-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 41:89–101 Lesche R, Kettschau G, Gromov AV, Bohnke N, Borkowski S, Monning U, Hegele-Hartung C, Dohr O, Dinkelborg LM, Graham K (2014) Preclinical evaluation of BAY 1075553, a novel F-18-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 41:89–101
Zurück zum Zitat Lewellen TK (1998) Time-of-flight PET. Semin Nucl Med 28 (3):268–275. doi:10.1016/s0001–2998(98)80031–7 Lewellen TK (1998) Time-of-flight PET. Semin Nucl Med 28 (3):268–275. doi:10.1016/s0001–2998(98)80031–7
Zurück zum Zitat Li ZB, Wu ZH, Chen K, Ryu EK, Chen XY (2008) F-18-labeled BBN-RGD heterodimer for prostate cancer imaging. Journal of Nuclear Medicine 49:453–361 Li ZB, Wu ZH, Chen K, Ryu EK, Chen XY (2008) F-18-labeled BBN-RGD heterodimer for prostate cancer imaging. Journal of Nuclear Medicine 49:453–361
Zurück zum Zitat Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Research 57:3629–3634 Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Research 57:3629–3634
Zurück zum Zitat Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Research 58:4055–3060 Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Research 58:4055–3060
Zurück zum Zitat Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57:108–111 Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57:108–111
Zurück zum Zitat Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. prostate cancer and Prostatic Diseases 9:230–234 Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. prostate cancer and Prostatic Diseases 9:230–234
Zurück zum Zitat Liu ZF, Li ZB, Cao QZ, Liu SL, Wang F, Chen XY (2009a) Small-animal PET of tumors with (64Cu)-labeled RGD-bombesin heterodimer. Journal of Nuclear Medicine 50:1168-1177 Liu ZF, Li ZB, Cao QZ, Liu SL, Wang F, Chen XY (2009a) Small-animal PET of tumors with (64Cu)-labeled RGD-bombesin heterodimer. Journal of Nuclear Medicine 50:1168-1177
Zurück zum Zitat Liu ZF, Niu G, Wang F, Chen XY (2009b) Ga-68-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging 36:1483–1494 Liu ZF, Niu G, Wang F, Chen XY (2009b) Ga-68-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging 36:1483–1494
Zurück zum Zitat Liu ZF, Yan YJ, Chin FT, Wang F, Chen XY (2009c) Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using F–18-labeled PEGylated RGD-Bombesin Heterodimer F-18-FB-PEG(3)-Glu-RGD-BBN. Journal of Medicinal Chemistry 52:425–332 Liu ZF, Yan YJ, Chin FT, Wang F, Chen XY (2009c) Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using F–18-labeled PEGylated RGD-Bombesin Heterodimer F-18-FB-PEG(3)-Glu-RGD-BBN. Journal of Medicinal Chemistry 52:425–332
Zurück zum Zitat Lottes G, Schober O (2000) Zur Geschichte der Nuklearmedizin – eine chronologische Darstellung der Ursprünge aus Naturwissenschaft, Technik und Medizin. Z Med Phys 10 (4):225–234 Lottes G, Schober O (2000) Zur Geschichte der Nuklearmedizin – eine chronologische Darstellung der Ursprünge aus Naturwissenschaft, Technik und Medizin. Z Med Phys 10 (4):225–234
Zurück zum Zitat Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research 62:4029–3033 Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research 62:4029–3033
Zurück zum Zitat Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of Cellular Physiology 202, 654–662 Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of Cellular Physiology 202, 654–662
Zurück zum Zitat Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis. Pathology & Oncology Research 15:167–172 Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis. Pathology & Oncology Research 15:167–172
Zurück zum Zitat Mansi R, Wang XJ, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR (2009) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240–5249 Mansi R, Wang XJ, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR (2009) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240–5249
Zurück zum Zitat Mansi R, Wang XJ, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38:97–107 Mansi R, Wang XJ, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38:97–107
Zurück zum Zitat Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG (2008) N-[N-[(S)–1,3-dicarboxypropyl]carbamoyl]-3-[F-18]fluorobenzyl-L-cysteine, [F-18]DCFBC: A new imaging probe for prostate cancer. Clinical Cancer Research 14:3036–3043 Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG (2008) N-[N-[(S)–1,3-dicarboxypropyl]carbamoyl]-3-[F-18]fluorobenzyl-L-cysteine, [F-18]DCFBC: A new imaging probe for prostate cancer. Clinical Cancer Research 14:3036–3043
Zurück zum Zitat Mehranian A, Arabi H, Zaidi H (2016) Vision 20/20: Magnetic resonance imaging-guided attenuation correction in PET/MRI: challenges, solutions, and opportunities. Medical Physics 43 (3):1130–1155. doi:doi:http://dx.doi.org/10.1118/1.4941014 Mehranian A, Arabi H, Zaidi H (2016) Vision 20/20: Magnetic resonance imaging-guided attenuation correction in PET/MRI: challenges, solutions, and opportunities. Medical Physics 43 (3):1130–1155. doi:doi:http://​dx.​doi.​org/​10.​1118/​1.​4941014
Zurück zum Zitat Mesters JR, Barinka C, Li WX, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. Embo Journal 25:1375–1384 Mesters JR, Barinka C, Li WX, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. Embo Journal 25:1375–1384
Zurück zum Zitat Mesters JR, Henning K, Hilgenfeld R (2007) Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallographica Section D-Biological Crystallography 63:508–513 Mesters JR, Henning K, Hilgenfeld R (2007) Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallographica Section D-Biological Crystallography 63:508–513
Zurück zum Zitat Metz CE (1978) Basic principles of ROC analysis. Semin Nucl Med 8 (4):283–298 Metz CE (1978) Basic principles of ROC analysis. Semin Nucl Med 8 (4):283–298
Zurück zum Zitat Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerJournal of Clinical Oncology 22:2522–2531 Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerJournal of Clinical Oncology 22:2522–2531
Zurück zum Zitat Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281–288 Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281–288
Zurück zum Zitat Molina-Duran F, Dinter D, Schoenahl F, Schoenberg SO, Glatting G (2014) Dependence of image quality on acquisition time for the PET-CT Biograph mCT. Z Med Phys 24 (1):73–79. doi:10.1016/j.zemedi.2013.03.002 Molina-Duran F, Dinter D, Schoenahl F, Schoenberg SO, Glatting G (2014) Dependence of image quality on acquisition time for the PET-CT Biograph mCT. Z Med Phys 24 (1):73–79. doi:10.1016/j.zemedi.2013.03.002
Zurück zum Zitat Morigi JJ, Stricker PD, van Leeuwen PJ, Tang RB, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L (2015) Prospective Comparison of F-18-Fluoromethylcholine vs. Ga-68-PSMA PET-CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. Journal of Nuclear Medicine 56:1185-1190 Morigi JJ, Stricker PD, van Leeuwen PJ, Tang RB, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L (2015) Prospective Comparison of F-18-Fluoromethylcholine vs. Ga-68-PSMA PET-CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. Journal of Nuclear Medicine 56:1185-1190
Zurück zum Zitat Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Smith CJ (2012) Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol 39:461–371 Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Smith CJ (2012) Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol 39:461–371
Zurück zum Zitat Nanni C, Schiavina R, Boschi S, Ambrosini V, Pettinato C, Brunocilla E, Martorana G, Fanti S (2013) Comparison of F-18-FACBC and C-11-choline PET-CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging 40:S11–S17 Nanni C, Schiavina R, Boschi S, Ambrosini V, Pettinato C, Brunocilla E, Martorana G, Fanti S (2013) Comparison of F-18-FACBC and C-11-choline PET-CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging 40:S11–S17
Zurück zum Zitat Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, Gentile G, Vagnoni V, Romagnoli D, Martorana G, Fanti S (2014) 18F-FACBC Compared with 11C-Choline PET-CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clinical Genitourinary Cancer 12:106–110 Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, Gentile G, Vagnoni V, Romagnoli D, Martorana G, Fanti S (2014) 18F-FACBC Compared with 11C-Choline PET-CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clinical Genitourinary Cancer 12:106–110
Zurück zum Zitat National Electrical Manufacturers Association (2007) Performance Measurements of Positron Emission Tomographs. In: NEMA Standards Publication NU 2–2007:S 1–6 National Electrical Manufacturers Association (2007) Performance Measurements of Positron Emission Tomographs. In: NEMA Standards Publication NU 2–2007:S 1–6
Zurück zum Zitat Nimmagadda S, Shield AF (2008) The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer and Metastasis Reviews 27:575–587 Nimmagadda S, Shield AF (2008) The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer and Metastasis Reviews 27:575–587
Zurück zum Zitat Nye JA, Schuster DM, Yu WP, Camp VM, Goodman MM, Votaw JR (2007) Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue Anti-F–18-FACBC in humans. Journal of Nuclear Medicine 48:1017–1020 Nye JA, Schuster DM, Yu WP, Camp VM, Goodman MM, Votaw JR (2007) Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue Anti-F–18-FACBC in humans. Journal of Nuclear Medicine 48:1017–1020
Zurück zum Zitat Odewole OA, Oyenuga OA, Tade F, Savir-Baruch B, Nieh PT, Master V, Chen ZJ, Wang XJ, Jani AB, Bellamy LM, Halkar RK, Goodman MM, Schuster DM (2015) Reproducibility and Reliability of Anti–3-[F–18]FACBC Uptake Measurements in Background Structures and Malignant Lesions on Follow-Up PET-CT in Prostate Carcinoma: an Exploratory Analysis. Molecular Imaging and Biology 17:277–283 Odewole OA, Oyenuga OA, Tade F, Savir-Baruch B, Nieh PT, Master V, Chen ZJ, Wang XJ, Jani AB, Bellamy LM, Halkar RK, Goodman MM, Schuster DM (2015) Reproducibility and Reliability of Anti–3-[F–18]FACBC Uptake Measurements in Background Structures and Malignant Lesions on Follow-Up PET-CT in Prostate Carcinoma: an Exploratory Analysis. Molecular Imaging and Biology 17:277–283
Zurück zum Zitat Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu WP, Votaw JR, Yoshida Y, Goodman MM, Ito O (2007) A preliminary study of anti–1-amino–3-F–18-fluorocyclobutyl–1-carboxylic acid for the detection of prostate cancer. Journal of Nuclear Medicine 48:46–55 Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu WP, Votaw JR, Yoshida Y, Goodman MM, Ito O (2007) A preliminary study of anti–1-amino–3-F–18-fluorocyclobutyl–1-carboxylic acid for the detection of prostate cancer. Journal of Nuclear Medicine 48:46–55
Zurück zum Zitat Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y (2012) Transport mechanisms of trans-1-amino-3-fluoro[1-C-14] cyclobutanecarboxylic acid in prostate cancer cells. Nuclear Medicine and Biology 39:109–119 Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y (2012) Transport mechanisms of trans-1-amino-3-fluoro[1-C-14] cyclobutanecarboxylic acid in prostate cancer cells. Nuclear Medicine and Biology 39:109–119
Zurück zum Zitat Okudaira H, Nakanishi T, Oka S, Kobayashi M, Tamagami H, Schuster DM, Goodman MM, Shirakami Y, Tamai I, Kawai K (2013) Kinetic analyses of trans–1-amino–3[F–18]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nuclear Medicine and Biology 40:670–675 Okudaira H, Nakanishi T, Oka S, Kobayashi M, Tamagami H, Schuster DM, Goodman MM, Shirakami Y, Tamai I, Kawai K (2013) Kinetic analyses of trans–1-amino–3[F–18]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nuclear Medicine and Biology 40:670–675
Zurück zum Zitat Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K (2002) C-11-acetate PET imaging of prostate cancer. Journal of Nuclear Medicine 43:181–186 Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K (2002) C-11-acetate PET imaging of prostate cancer. Journal of Nuclear Medicine 43:181–186
Zurück zum Zitat Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, Sadato N, Yonekura Y, Okada K (2001) FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nuclear Medicine Communications 22, 963–969 Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, Sadato N, Yonekura Y, Okada K (2001) FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nuclear Medicine Communications 22, 963–969
Zurück zum Zitat Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, Gentile V, Laghi A, Passariello R (2012) Prostate cancer: 1HMRS-DCEMR at 3 T vs. [18F]choline PET-CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). European Journal of Radiology 81:700–708 Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, Gentile V, Laghi A, Passariello R (2012) Prostate cancer: 1HMRS-DCEMR at 3 T vs. [18F]choline PET-CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). European Journal of Radiology 81:700–708
Zurück zum Zitat Perkins AC, Missailidis S (2007) Radiolabelled aptamers for tumour imaging and therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging 51:292–296 Perkins AC, Missailidis S (2007) Radiolabelled aptamers for tumour imaging and therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging 51:292–296
Zurück zum Zitat Perner S, Hofer MD, Kim R, Shah RB, Li HJ, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathology 38:696–701 Perner S, Hofer MD, Kim R, Shah RB, Li HJ, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathology 38:696–701
Zurück zum Zitat Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM (1975) Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16 (3):210–224 Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM (1975) Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16 (3):210–224
Zurück zum Zitat Pomper MG, Musachio JL, Zhang JZ, Scheffel U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF, Kozikowski AP (2002) C-11-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Molecular Imaging 1:96–101 Pomper MG, Musachio JL, Zhang JZ, Scheffel U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF, Kozikowski AP (2002) C-11-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Molecular Imaging 1:96–101
Zurück zum Zitat Preylowski V, Schlögl S, Schoenahl F, Jörg G, Samnick S, Buck AK, Lassmann M (2013) Is the Image Quality of I–124-PET Impaired by an Automatic Correction of Prompt Gammas? PLoS ONE 8 (8):e71729. doi:10.1371/journal.pone.0071729 Preylowski V, Schlögl S, Schoenahl F, Jörg G, Samnick S, Buck AK, Lassmann M (2013) Is the Image Quality of I–124-PET Impaired by an Automatic Correction of Prompt Gammas? PLoS ONE 8 (8):e71729. doi:10.1371/journal.pone.0071729
Zurück zum Zitat Qi J, Leahy RM (2006) Iterative reconstruction techniques in emission computed tomography. Phys Med Biol 51 (15):541–578 Qi J, Leahy RM (2006) Iterative reconstruction techniques in emission computed tomography. Phys Med Biol 51 (15):541–578
Zurück zum Zitat Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS (2008) Trends in Gleason score: Concordance between biopsy and prostatectomy over 15 years. Urology 72:177–182 Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS (2008) Trends in Gleason score: Concordance between biopsy and prostatectomy over 15 years. Urology 72:177–182
Zurück zum Zitat Ratib O, Beyer T (2011) Whole-body hybrid PET/MRI: ready for clinical use? Eur J Nucl Med Mol Imaging 38 (6):992–995 Ratib O, Beyer T (2011) Whole-body hybrid PET/MRI: ready for clinical use? Eur J Nucl Med Mol Imaging 38 (6):992–995
Zurück zum Zitat Rausch I, Cal-Gonzalez J, Dapra D, Gallowitsch H, Lind P, Beyer T, Minear G (2015) Performance evaluation of the Biograph mCT Flow PET-CT system according to the NEMA NU2–2012 standard. EJNMMI Physics 2 (1):26 Rausch I, Cal-Gonzalez J, Dapra D, Gallowitsch H, Lind P, Beyer T, Minear G (2015) Performance evaluation of the Biograph mCT Flow PET-CT system according to the NEMA NU2–2012 standard. EJNMMI Physics 2 (1):26
Zurück zum Zitat Reubi JC, Fleischmann A, Waser B, Rehmann R (2011) Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: Molecular basis for dual targeting of tumoral vasculature. Peptides 32:1457–1462 Reubi JC, Fleischmann A, Waser B, Rehmann R (2011) Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: Molecular basis for dual targeting of tumoral vasculature. Peptides 32:1457–1462
Zurück zum Zitat Reubi JC, Gugger M, Waser B (2002a) Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 29:855–862 Reubi JC, Gugger M, Waser B (2002a) Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 29:855–862
Zurück zum Zitat Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49:1735–1738 Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49:1735–1738
Zurück zum Zitat Reubi JC, Maecke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46:67s–75s Reubi JC, Maecke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46:67s–75s
Zurück zum Zitat Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 30:781–793 Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 30:781–793
Zurück zum Zitat Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M (2002b) Bombesin receptor subtypes in human cancers: Detection with the universal radioligand I–125-[D-TYR6, beta-ALA(11), PHE13, NLE14] bombesin(6–14). Clin Cancer Res 8:1139–1146 Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M (2002b) Bombesin receptor subtypes in human cancers: Detection with the universal radioligand I–125-[D-TYR6, beta-ALA(11), PHE13, NLE14] bombesin(6–14). Clin Cancer Res 8:1139–1146
Zurück zum Zitat Rockey WM, Huang L, Kloepping KC, Baumhover NJ, Giangrande PH, Schultz MK (2011) Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper–64 for targeted molecular imaging. Bioorganic & Medicinal Chemistry 19:4080–3090 Rockey WM, Huang L, Kloepping KC, Baumhover NJ, Giangrande PH, Schultz MK (2011) Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper–64 for targeted molecular imaging. Bioorganic & Medicinal Chemistry 19:4080–3090
Zurück zum Zitat Ross JS, Sheehan CE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clinical Cancer Research 9:6357–6362 Ross JS, Sheehan CE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clinical Cancer Research 9:6357–6362
Zurück zum Zitat Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M (2003) Fatty acid synthase molecular signatures expression defines distinct in prostate cancer. Molecular Cancer Research 1, 707–715 Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M (2003) Fatty acid synthase molecular signatures expression defines distinct in prostate cancer. Molecular Cancer Research 1, 707–715
Zurück zum Zitat Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY (2015) F-18-DCFBC PET-CT for PSMA-based detection and characterization of primary prostate cancer. Journal of Nuclear Medicine 56:1003–1010 Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY (2015) F-18-DCFBC PET-CT for PSMA-based detection and characterization of primary prostate cancer. Journal of Nuclear Medicine 56:1003–1010
Zurück zum Zitat Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J(2011) Targeting the Internal Epitope of prostate-specific membrane antigen with Zr-89-7E11 Immuno-PET. Journal of Nuclear Medicine 52:1608–1615 Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J(2011) Targeting the Internal Epitope of prostate-specific membrane antigen with Zr-89-7E11 Immuno-PET. Journal of Nuclear Medicine 52:1608–1615
Zurück zum Zitat Rybalov M, Ananias, HJK, Hoving, HD, van der Poel HG, Rosati S, de Jong IJ (2014) PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent prostate cancer after Radiotherapy. International Journal of Molecular Sciences 15:6046–6061 Rybalov M, Ananias, HJK, Hoving, HD, van der Poel HG, Rosati S, de Jong IJ (2014) PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent prostate cancer after Radiotherapy. International Journal of Molecular Sciences 15:6046–6061
Zurück zum Zitat Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A (2016) 68Ga-PSMA–11 dynamic PET-CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging epub ahead of print 12.01.2016:1–12. doi:10.1007/s00259–015–3302–3 Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A (2016) 68Ga-PSMA–11 dynamic PET-CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging epub ahead of print 12.01.2016:1–12. doi:10.1007/s00259–015–3302–3
Zurück zum Zitat Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R (2002) Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncologica 41:425–329 Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R (2002) Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncologica 41:425–329
Zurück zum Zitat Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE (2011) Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Modern Pathology 24:1521–1529 Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE (2011) Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Modern Pathology 24:1521–1529
Zurück zum Zitat Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU (2006) Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67:996–1000 Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU (2006) Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67:996–1000
Zurück zum Zitat Schafer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U, Eisenhut M, Eder M (2012) A dimerized urea-based inhibitor of the prostate-specific membrane antigen for Ga-68-PET imaging of prostate cancer. EJNMMI Res 2 Schafer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U, Eisenhut M, Eder M (2012) A dimerized urea-based inhibitor of the prostate-specific membrane antigen for Ga-68-PET imaging of prostate cancer. EJNMMI Res 2
Zurück zum Zitat Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Fdn PC (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446 Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Fdn PC (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446
Zurück zum Zitat Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, Dahlbom M (2008) 11C-acetate kinetics of prostate cancer. Journal of Nuclear Medicine 49:206–215 Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, Dahlbom M (2008) 11C-acetate kinetics of prostate cancer. Journal of Nuclear Medicine 49:206–215
Zurück zum Zitat Schlegel W, Bille J (2002) Medizinische Physik 2. Springer, Berlin Heidelberg Schlegel W, Bille J (2002) Medizinische Physik 2. Springer, Berlin Heidelberg
Zurück zum Zitat Schmidlin P, Doll J (1991) Implementation of iterative reconstruction in positron emission tomography. In: Information processing in medical imaging. Wiley, S 59–67 Schmidlin P, Doll J (1991) Implementation of iterative reconstruction in positron emission tomography. In: Information processing in medical imaging. Wiley, S 59–67
Zurück zum Zitat Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, Lewis MM, Nye JA, Yu WP, Bowman FD, Goodman MM (2011) Detection of Recurrent Prostate Carcinoma with anti–1-Amino–3-F–18-Fluorocyclobutane–1-Carboxylic Acid PET-CT and In-111-Capromab Pendetide SPECT/CT. Radiology 259, 852–861 Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, Lewis MM, Nye JA, Yu WP, Bowman FD, Goodman MM (2011) Detection of Recurrent Prostate Carcinoma with anti–1-Amino–3-F–18-Fluorocyclobutane–1-Carboxylic Acid PET-CT and In-111-Capromab Pendetide SPECT/CT. Radiology 259, 852–861
Zurück zum Zitat Schuster DM, Votaw JR, Nieh PT, Yu WP, Nye JA, Master V, Bowman FD, Issa MM, Goodman MM (2007) Initial experience with the radiotracer anti–1-amino–3-F–18-fluorocyclobutane–1-carboxylic acid with PET-CT in prostate carcinoma. Journal of Nuclear Medicine 48:56–63 Schuster DM, Votaw JR, Nieh PT, Yu WP, Nye JA, Master V, Bowman FD, Issa MM, Goodman MM (2007) Initial experience with the radiotracer anti–1-amino–3-F–18-fluorocyclobutane–1-carboxylic acid with PET-CT in prostate carcinoma. Journal of Nuclear Medicine 48:56–63
Zurück zum Zitat Shao Y, Cherry SR, Farahani K, Meadors K, Siegel S, Silverman RW, Marsden PK (1997) Simultaneous PET and MR imaging. Phys Med Biol 42 (10):1965–1970 Shao Y, Cherry SR, Farahani K, Meadors K, Siegel S, Silverman RW, Marsden PK (1997) Simultaneous PET and MR imaging. Phys Med Biol 42 (10):1965–1970
Zurück zum Zitat Shields AF (2006) Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology. Molecular Imaging and Biology 8:141–150 Shields AF (2006) Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology. Molecular Imaging and Biology 8:141–150
Zurück zum Zitat Silver DA, Pellicer I, Fair WR, Heston WDW, CordonCardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical Cancer Research 3:81–85 Silver DA, Pellicer I, Fair WR, Heston WDW, CordonCardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical Cancer Research 3:81–85
Zurück zum Zitat Slomka P, Baum R (2009) Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imag 36 (0):44–55. doi:10.1007/s00259–008–0941–8 Slomka P, Baum R (2009) Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imag 36 (0):44–55. doi:10.1007/s00259–008–0941–8
Zurück zum Zitat Slomka PJ, Pan T, Germano G (2016) Recent Advances and Future Progress in PET Instrumentation. Seminars in Nuclear Medicine 46 (1):5–19. doi:10.1053/j.semnuclmed.2015.09.006 Slomka PJ, Pan T, Germano G (2016) Recent Advances and Future Progress in PET Instrumentation. Seminars in Nuclear Medicine 46 (1):5–19. doi:10.1053/j.semnuclmed.2015.09.006
Zurück zum Zitat Smith TAD (2000) Mammalian hexokinases and their abnormal expression in cancer. British Journal of Biomedical Science 57:170–178 Smith TAD (2000) Mammalian hexokinases and their abnormal expression in cancer. British Journal of Biomedical Science 57:170–178
Zurück zum Zitat Strand SE, Zanzonico P, Johnson TK (1993) Pharmacokinetic modeling. Med Phys 20 (2 Pt 2):515–527 Strand SE, Zanzonico P, Johnson TK (1993) Pharmacokinetic modeling. Med Phys 20 (2 Pt 2):515–527
Zurück zum Zitat Sun HH, Mangne TJ, Collin JM, Muzi O, Dougla K, Shield AF (2005a) Imaging DNA synthesis in vivo with F–18-FMAU and PET. Journal of Nuclear Medicine 46:292–296 Sun HH, Mangne TJ, Collin JM, Muzi O, Dougla K, Shield AF (2005a) Imaging DNA synthesis in vivo with F–18-FMAU and PET. Journal of Nuclear Medicine 46:292–296
Zurück zum Zitat Sun HH, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, Douglas K, Shields AF (2005b) Imaging DNA synthesis with [F-18]FMAU and positron emission tomography in patients with cancer. European Journal of Nuclear Medicine and Molecular Imaging 32:15–22 Sun HH, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, Douglas K, Shields AF (2005b) Imaging DNA synthesis with [F-18]FMAU and positron emission tomography in patients with cancer. European Journal of Nuclear Medicine and Molecular Imaging 32:15–22
Zurück zum Zitat Surti S, Karp JS (2016) Advances in time-of-flight PET. Physica Medica 32 (1):12–22. doi:http://dx.doi.org/10.1016/j.ejmp.2015.12.007 Surti S, Karp JS (2016) Advances in time-of-flight PET. Physica Medica 32 (1):12–22. doi:http://​dx.​doi.​org/​10.​1016/​j.​ejmp.​2015.​12.​007
Zurück zum Zitat Surti S, Karp JS, Freifelder R, Liu F (2000) Optimizing the performance of a PET detector using discrete GSO crystals on a continuous lightguide. IEEE Trans Nucl Sci 47:1030–1036 Surti S, Karp JS, Freifelder R, Liu F (2000) Optimizing the performance of a PET detector using discrete GSO crystals on a continuous lightguide. IEEE Trans Nucl Sci 47:1030–1036
Zurück zum Zitat Surti S, Karp JS, Popescu LM, Daube-Witherspoon ME, Werner M (2006) Investigation of time-of-flight benefit for fully 3-D PET. IEEE Trans Med Imaging 25 (5):529–538. doi:10.1109/tmi.2006.871419 Surti S, Karp JS, Popescu LM, Daube-Witherspoon ME, Werner M (2006) Investigation of time-of-flight benefit for fully 3-D PET. IEEE Trans Med Imaging 25 (5):529–538. doi:10.1109/tmi.2006.871419
Zurück zum Zitat Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, Minn H (2004) Kinetics of [C-11]choline uptake in prostate cancer: a PET stydy. European Journal of Nuclear Medicine and Molecular Imaging 31:317–324 Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, Minn H (2004) Kinetics of [C-11]choline uptake in prostate cancer: a PET stydy. European Journal of Nuclear Medicine and Molecular Imaging 31:317–324
Zurück zum Zitat Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG (2015) Initial evaluation of [F–18]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Molecular Imaging and Biology 17:565–574 Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG (2015) Initial evaluation of [F–18]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Molecular Imaging and Biology 17:565–574
Zurück zum Zitat Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH (2010) Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116:1075–1083 Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH (2010) Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116:1075–1083
Zurück zum Zitat Tavitian B, Duconge F, Boisgard R, Dolle F (2009) In vivo imaging of oligonucleotidic aptamers. Methods Mol Biol 535:241–259 Tavitian B, Duconge F, Boisgard R, Dolle F (2009) In vivo imaging of oligonucleotidic aptamers. Methods Mol Biol 535:241–259
Zurück zum Zitat Ter-Pogossian MM, Mullani NA, Ficke DC, Markham J, Snyder DL (1981) Photon time-of-flight-assisted positron emission tomography. J Comput Assist Tomogr 5 (2):227–239. doi:10.1097/00004728–198104000–00014 Ter-Pogossian MM, Mullani NA, Ficke DC, Markham J, Snyder DL (1981) Photon time-of-flight-assisted positron emission tomography. J Comput Assist Tomogr 5 (2):227–239. doi:10.1097/00004728–198104000–00014
Zurück zum Zitat Troyer JK, Beckett ML, Wright GL (1995a) Detection and characterization of the prostate-specific membrane antigen (Pmsa) in tissue-extracts and body-fluids. International Journal of Cancer 62:552–558 Troyer JK, Beckett ML, Wright GL (1995a) Detection and characterization of the prostate-specific membrane antigen (Pmsa) in tissue-extracts and body-fluids. International Journal of Cancer 62:552–558
Zurück zum Zitat Troyer JK, Beckett ML, Wright GL (1997) Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232–242 Troyer JK, Beckett ML, Wright GL (1997) Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232–242
Zurück zum Zitat Troyer JK, Feng Q, Beckett ML, Wright GL Jr (1995b) Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1:29–37 Troyer JK, Feng Q, Beckett ML, Wright GL Jr (1995b) Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1:29–37
Zurück zum Zitat Turkbey B, Mena E, Shih J, Pinto PA, Merino MJ, Lindenberg ML, Bernardo M, McKinney YL, Adler S, Owenius R, Choyke PL, Kurdziel KA (2014) Localized prostate cancer detection with F-18 FACBC PET-CT: comparison with MR imaging and histopathologic analysis. Radiology 270:849–856 Turkbey B, Mena E, Shih J, Pinto PA, Merino MJ, Lindenberg ML, Bernardo M, McKinney YL, Adler S, Owenius R, Choyke PL, Kurdziel KA (2014) Localized prostate cancer detection with F-18 FACBC PET-CT: comparison with MR imaging and histopathologic analysis. Radiology 270:849–856
Zurück zum Zitat Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM (2013) The Role of 11-C-Choline and 18-F-Fluorocholine positron emission tomography (PET) and PET-CT in prostate cancer: a systematic review and meta-analysis. European Urology 64:106–117 Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM (2013) The Role of 11-C-Choline and 18-F-Fluorocholine positron emission tomography (PET) and PET-CT in prostate cancer: a systematic review and meta-analysis. European Urology 64:106–117
Zurück zum Zitat Vali R, Loidl W, Pirich C, Langesteger W, Beheshti M (2015) Imaging of prostate cancer with PET-CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging 5:96–108 Vali R, Loidl W, Pirich C, Langesteger W, Beheshti M (2015) Imaging of prostate cancer with PET-CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging 5:96–108
Zurück zum Zitat Vandenberghe S, Daube-Witherspoon ME, Lewitt RM, Karp JS (2006) Fast reconstruction of 3D time-of-flight PET data by axial rebinning and transverse mashing. Phys Med Biol 51 (6):1603–1621. doi:10.1088/0031–9155/51/6/017 Vandenberghe S, Daube-Witherspoon ME, Lewitt RM, Karp JS (2006) Fast reconstruction of 3D time-of-flight PET data by axial rebinning and transverse mashing. Phys Med Biol 51 (6):1603–1621. doi:10.1088/0031–9155/51/6/017
Zurück zum Zitat Vandenberghe S, Mikhaylova E, D’Hoe E, Mollet P, Karp JS (2016) Recent developments in time-of-flight PET. EJNMMI Phys 3 (1):1–30. doi:10.1186/s40658–016–0138–3 Vandenberghe S, Mikhaylova E, D’Hoe E, Mollet P, Karp JS (2016) Recent developments in time-of-flight PET. EJNMMI Phys 3 (1):1–30. doi:10.1186/s40658–016–0138–3
Zurück zum Zitat Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H (2014) Bone Metastases in Castration-Resistant prostate cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. Radiology 271:220–229 Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H (2014) Bone Metastases in Castration-Resistant prostate cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. Radiology 271:220–229
Zurück zum Zitat Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS (2014) Noninvasive imaging of PSMA in prostate tumors with Zr-89-labeled huJ591 engineered antibody fragments: the faster alternatives. Molecular Pharmaceutics 11:3965–3973 Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS (2014) Noninvasive imaging of PSMA in prostate tumors with Zr-89-labeled huJ591 engineered antibody fragments: the faster alternatives. Molecular Pharmaceutics 11:3965–3973
Zurück zum Zitat Visser EP, Boerman OC, Oyen WJG (2010) SUV: From Silly Useless Value to Smart Uptake Value. J Nucl Med 51 (2):173–175. doi:10.2967/jnumed.109.068411 Visser EP, Boerman OC, Oyen WJG (2010) SUV: From Silly Useless Value to Smart Uptake Value. J Nucl Med 51 (2):173–175. doi:10.2967/jnumed.109.068411
Zurück zum Zitat Wan H, Olive P, Na L, Wan SY, Wan Z, Rhi JK, Zhan RW, Hill DL (2002) Radiolabeled 2’-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2’-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemotherapy and Pharmacology 49:419–324 Wan H, Olive P, Na L, Wan SY, Wan Z, Rhi JK, Zhan RW, Hill DL (2002) Radiolabeled 2’-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2’-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemotherapy and Pharmacology 49:419–324
Zurück zum Zitat Wang WL, Tavora F, Sharma R, Eisenberger M, Netto GJ (2009) PSMA expression in Schwannoma: A potenzial clinical mimicker of metastatic prostate carcinoma. Urologic Oncology-Seminars and Original Investigations 27:525–528 Wang WL, Tavora F, Sharma R, Eisenberger M, Netto GJ (2009) PSMA expression in Schwannoma: A potenzial clinical mimicker of metastatic prostate carcinoma. Urologic Oncology-Seminars and Original Investigations 27:525–528
Zurück zum Zitat Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA (2014) Positron Emission Tomography (PET) imaging of prostate cancer with a Gastrin releasing peptide receptor antagonist – from mice to men. Theranostics 4:412–319 Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA (2014) Positron Emission Tomography (PET) imaging of prostate cancer with a Gastrin releasing peptide receptor antagonist – from mice to men. Theranostics 4:412–319
Zurück zum Zitat Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334 Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334
Zurück zum Zitat Wright GL Jr, Haley C, Beckett ML, Schellhammer PF (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18–28 Wright GL Jr, Haley C, Beckett ML, Schellhammer PF (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18–28
Zurück zum Zitat Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, Purnell G, Tyson I, Heal A, Abdelnabi H, Winzelberg G (1991) Immunoscintigraphy of prostatic cancer - preliminary-results with in-111-labeled monoclonal-antibody 7e11-C5.3 (Cyt–356). Prostate 18:229–241 Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, Purnell G, Tyson I, Heal A, Abdelnabi H, Winzelberg G (1991) Immunoscintigraphy of prostatic cancer - preliminary-results with in-111-labeled monoclonal-antibody 7e11-C5.3 (Cyt–356). Prostate 18:229–241
Zurück zum Zitat Yan YJ, Chen K, Yang M, Sun XL, Liu SL, Chen XY (2011) A new F-18-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 41:439–347 Yan YJ, Chen K, Yang M, Sun XL, Liu SL, Chen XY (2011) A new F-18-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 41:439–347
Zurück zum Zitat Yao V, Bacich DJ (2006) Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 66:867–875 Yao V, Bacich DJ (2006) Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 66:867–875
Zurück zum Zitat Yao V, Berkman CE, Choi JK, O’Keefe DS, Bacich DJ (2010) Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 70:305–316 Yao V, Berkman CE, Choi JK, O’Keefe DS, Bacich DJ (2010) Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 70:305–316
Zurück zum Zitat Yao V, Parwani A, Maier C, Heston WD, Bacich DJ (2008) Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Research 68:9070–9077 Yao V, Parwani A, Maier C, Heston WD, Bacich DJ (2008) Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Research 68:9070–9077
Zurück zum Zitat Yu, EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA (2011) C11-Acetate and F–18 FDG PET for Men With prostate cancer Bone Metastases Relative Findings and Response to Therapy. Clinical Nuclear Medicine 36:192–198 Yu, EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA (2011) C11-Acetate and F–18 FDG PET for Men With prostate cancer Bone Metastases Relative Findings and Response to Therapy. Clinical Nuclear Medicine 36:192–198
Zurück zum Zitat Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, Squire O, Morris M, Scher H, McCarthy T, Welch M, Larson SM, Humm JL (2004) PET-based radiation dosimetry in man of F-18-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. Journal of Nuclear Medicine 45:1966–1971 Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, Squire O, Morris M, Scher H, McCarthy T, Welch M, Larson SM, Humm JL (2004) PET-based radiation dosimetry in man of F-18-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. Journal of Nuclear Medicine 45:1966–1971
Zurück zum Zitat Zhou J, Neale JH, Pomper MG, Kozikowski AP (2005) NAAG peptidase inhibitors and their potenzial for diagnosis and therapy. Nature Reviews Drug Discovery 4:1015–1026 Zhou J, Neale JH, Pomper MG, Kozikowski AP (2005) NAAG peptidase inhibitors and their potenzial for diagnosis and therapy. Nature Reviews Drug Discovery 4:1015–1026
Zurück zum Zitat Zhu L, Niu G, Fang X, Chen X (2010) Preclinical molecular imaging of tumor angiogenesis. Quarterly Journal of Nuclear Medicine and Molecular Imaging 54:291–308 Zhu L, Niu G, Fang X, Chen X (2010) Preclinical molecular imaging of tumor angiogenesis. Quarterly Journal of Nuclear Medicine and Molecular Imaging 54:291–308
Zurück zum Zitat Ziegler SI (2007) Instrumentierung: SPECT, PET, PET-CT. In: Krause B-J, Schwaiger M, Buck AK (Hrsg) Nuklearmedizinische Onkologie. ecomed, 1. Aufl. Hüthig Jehle Rehm, Landsberg, S 17–24 Ziegler SI (2007) Instrumentierung: SPECT, PET, PET-CT. In: Krause B-J, Schwaiger M, Buck AK (Hrsg) Nuklearmedizinische Onkologie. ecomed, 1. Aufl. Hüthig Jehle Rehm, Landsberg, S 17–24
Zurück zum Zitat Ziegler SI, Pichler BJ (2000) Neue technische Entwicklungen in der Nuklearmedizin. Z Med Phys 10 (4):237–245 Ziegler SI, Pichler BJ (2000) Neue technische Entwicklungen in der Nuklearmedizin. Z Med Phys 10 (4):237–245
Metadaten
Titel
Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie
verfasst von
Prof. Dr. Gerhard Glatting
PD Dr. rer.nat. Carmen Wängler
Prof. Dr. rer. nat. Björn Wängler
Copyright-Jahr
2017
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-50468-0_2

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.